BI
KALV

BVF Inc’s KalVista Pharmaceuticals KALV Stock Holding History

BVF Inc’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-252,693
Closed -$4.99M – 55
2018
Q4 		$4.99M Sell
252,693
-356,321
-59% -$7.16M 0.65% 39
2018
Q3 		$13.5M Buy
+609,014
New +$8.23M 1.18% 32

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc's KALV Position: Q1 2019 in Review

BVF Inc sold out of KalVista Pharmaceuticals (KALV) in Q1 2019, closing a stake of 252,693 shares — an estimated $4.99M sold.

BVF Inc first reported a position in KALV in Q3 2018 and held it in 2 quarters. The position peaked at $13.5M in Q3 2018. 68 funds tracked by Wall St. Rank hold KALV as of Q1 2019.

  • BVF Inc reported no remaining KalVista Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • BVF Inc sold 252,693 KalVista Pharmaceuticals shares in Q1 2019, an estimated $4.99M.
  • BVF Inc first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • BVF Inc's KalVista Pharmaceuticals position peaked at $13.5M in Q3 2018.
  • 68 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2019.

Based on BVF Inc's 13F filing for Q1 2019, filed 15 May 2019.